Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 4Withdrawn 1Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Glioma 2Simpson-Golabi-Behmel syndrome 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Carcinoma, Hepatocellular 1

Interventions

Sorafenib 13Radiosurgery 9spartalizumab 7lenvatinib 7Oxaliplatin 6Gemcitabine 5Fluorouracil 5Radiotherapy 4Cisplatin 4Bevacizumab 4atezolizumab 3Leucovorin 3Folfox protocol 3Doxorubicin 3gadolinium ethoxybenzyl DTPA 2fludarabine 2cabozantinib 2Nivolumab 2Mitomycin 2Electroporation 2Cyclophosphamide 2Chemoembolization, Therapeutic 2tremelimumab 1toripalimab 1tocilizumab 1tislelizumab 1temsirolimus 1tazemetostat 1sitravatinib 1pirarubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Carcinoma, Hepatocellular × Immunotherapy, Adoptive × Clear all
NCT02723942 2020-07-16

CAR-T Cell Immunotherapy for HCC Targeting GPC3

Fuda Cancer Hospital, Guangzhou

Phase 1/2 Withdrawn
Gastrointestinal

Simpson-Golabi-Behmel syndrome, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡